The Directors (together with their families and their family trusts and pension scheme and other arrangements) in aggregate hold 596,379 ordinary shares in the Company, representing 1.0% of the Company’s current issued share capital. 1.0% of the issued share capital is not in public hands. The Company has been made aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares:
|Number of ordinary shares||% of issued share capital|
|Obotritia Capital KGaA||7.84%|
|Octopus Investments Nominees Ltd||5.89%|
|Rosetta Capital VI GP LP, on behalf of Rosetta Capital VI, LP||5.65%|
|Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP||5.27%|
The above information was last updated on Monday 30 January 2023.